XORTX Therapeutics is a late clinical-stage biotechnology company focused on identifying, developing and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan (rate) disease indications. Co.'s three primary product candidates are: XRx-008, a program for the treatment of autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury associated with severe virus infection and associated health consequences; and XRx-225, a program for the treatment of type 2 diabetic nephropathy. The XRTX average annual return since 2021 is shown above.
The Average Annual Return on the XRTX average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether XRTX average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the XRTX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|